2 Healthcare Stocks to look at – MVP and FPH

Healthcare Stocks - Kalkine media

Medical Developments International Ltd (ASX: MVP) is a pain relief drug maker. It has a pharmaceutical drug business and, medical and veterinary equipment business. It is engaged both into manufacturing and distribution of medical and veterinary equipment, and a pharmaceutical drug. The company has three segments pharmaceuticals, medical devices and veterinary products. The company’s stock traded around $3.960 with a daily price change of -$0.020 and percentage change of -0.503%, as at August 17, 2018, market open. The annual dividend yield for the stock is 1% which is fully franked. The most recent dividend declared and paid was 2 cents with dividend ex-date as March 02, 2018 and dividend pay-date as April 13, 2018. Over the past 1 year, the stock has seen a performance change of -22%. Primarily, FDA has put the approval for clinical program for Penthrox for sale in the USA on hold and a letter outlining outstanding issues and concerns is to be issued, as advised by the FDA. For more than 30 years in Australia and with more than 6.0 million units sold, Penthrox has been used safely and effectively. The company is seeking at $4 each, 4.2 million Medical Developments shares discounted by 1%.

[optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

Meanwhile, the group has announced its FY18 results, wherein the net revenue for the year from ordinary activities has been down 4.8% while net profit after tax has plunged by 86.6%. A final dividend of 2 cents per share has been declared to be paid in the month of October 2018.

Fisher and Paykel Healthcare Corporation Ltd (ASX: FPH), a medical devices and systems player known across the world, saw its stock trading around $13.52 with a daily price change of $0.030 or 0.22%, as at August 17, 2018, market open. The Group reported an increase of 12 per cent over the previous year in the net profit after tax that amounted to NZ$190.2 million for the year ended 31 March 2018. The operating revenue was at record NZ$980.8 million, 10 per cent above the prior year, with 87 per cent of revenue contributed from recurring items, such as consumables and accessories. The Board approved an increased fully imputed final dividend of 12.50 cents per share and with this, the total dividends for the year amounted to 21.25 cents per share and it recorded an increase of 9 per cent on the previous year. Moreover, gross margin, at 66.3 per cent, increased by 31 basis points due to a favorable product mix and increased volume from the Mexican manufacturing facility.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report